文献速递癫痫

儿童失神癫痫抗癫痫药物疗效的药物遗传学研究

Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy.
PubMed 文献 · Ann Neurol · 2017-01-01

该研究基于446例儿童失神癫痫患儿的随机双盲试验,分析CACNA1G、CACNA1H、CACNA1I和ABCB1基因多态性与乙琥胺、拉莫三嗪、丙戊酸短期癫痫发作结局的关联。结果显示乙琥胺和拉莫三嗪的疗效与特定基因变异相关,丙戊酸则无显著关联,体外电生理实验证实P640L变异影响乙琥胺对T型钙通道的作用。

要点

  • CACNA1H rs61734410和CACNA1I rs3747178与乙琥胺疗效差相关。
  • ABCB1 rs2032582与拉莫三嗪疗效差相关,CACNA1H rs2753326/rs2753325与疗效好相关。
  • 丙戊酸疗效未发现与常见基因多态性关联。

核心结论

  • 四种T型钙通道变异和一种ABCB1转运体变异与儿童失神癫痫的药物反应差异相关。
  • P640L变异对乙琥胺效应的影响在体外电生理实验中得到验证。
  • 遗传变异可能在儿童失神癫痫药物反应差异中起作用。

研究设计与样本

  • 采用随机双盲试验,纳入446例儿童失神癫痫患儿,比较乙琥胺、拉莫三嗪和丙戊酸的短期癫痫发作结局。
  • 评估4个基因中次要等位基因频率≥15%的多态性与癫痫发作结局的关联。
  • 对转染的CACNA1H通道进行体外电生理实验,确定一个变异对乙琥胺反应的影响。

主要发现

  • 乙琥胺组中,CACNA1H rs61734410/P640L在未无发作参与者中更常见(p=0.011,OR=2.63,95% CL=1.25-5.56)。
  • 乙琥胺组中,CACNA1I rs3747178在未无发作参与者中更常见(p=0.026,OR=2.38,95% CL=1.11-5.00)。
  • 拉莫三嗪组中,ABCB1 rs2032582/S893A在未无发作参与者中更常见(p=0.015,OR=2.22,95% CL=1.16-4.17)。
  • 拉莫三嗪组中,CACNA1H rs2753326和rs2753325在无发作参与者中更常见(p=0.038,OR=0.52,95% CL=0.28-0.96)。

关键数值与推荐

  • 乙琥胺组:CACNA1H rs61734410/P640L与未无发作相关,p=0.011,OR=2.63,95% CL=1.25-5.56。
  • 乙琥胺组:CACNA1I rs3747178与未无发作相关,p=0.026,OR=2.38,95% CL=1.11-5.00。
  • 拉莫三嗪组:ABCB1 rs2032582/S893A与未无发作相关,p=0.015,OR=2.22,95% CL=1.16-4.17。
  • 拉莫三嗪组:CACNA1H rs2753326和rs2753325与无发作相关,p=0.038,OR=0.52,95% CL=0.28-0.96。
  • 丙戊酸组:未发现与癫痫发作状态相关的常见多态性。

临床怎么用

  • 对于儿童失神癫痫患者,CACNA1H和CACNA1I特定变异可能提示乙琥胺疗效较差。
  • ABCB1 rs2032582可能提示拉莫三嗪疗效较差,而CACNA1H rs2753326/rs2753325可能提示拉莫三嗪疗效较好。
  • 丙戊酸目前未发现相关遗传标记,选择药物时仍需综合临床因素。

局限性

  • 研究仅评估短期癫痫发作结局,长期疗效未涉及。
  • 仅分析了4个基因中常见多态性,未覆盖其他潜在相关基因。
  • 体外实验仅针对一个变异,其他变异的机制未验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether common polymorphisms in CACNA1G, CACNA1H, CACNA1I, and ABCB1 are associated with differential short-term seizure outcome in childhood absence epilepsy (CAE). METHODS: Four hundred forty-six CAE children in a randomized double-blind trial of ethosuximide, lamotrigine, and valproate had short-term seizure outcome determined. Associations between polymorphisms (minor allele frequency ≥ 15%) in 4 genes and seizure outcomes were assessed. In vitro electrophysiology on transfected CACNA1H channels determined impact of 1 variant on T-type calcium channel responsiveness to ethosuximide. RESULTS: Eighty percent (357 of 446) of subjects had informative short-term seizure status (242 seizure free, 115 not seizure free). In ethosuximide subjects, 2 polymorphisms (CACNA1H rs61734410/P640L, CACNA1I rs3747178) appeared more commonly among not-seizure-free participants (p = 0.011, odds ratio [OR] = 2.63, 95% confidence limits [CL] = 1.25-5.56; p = 0.026, OR = 2.38, 95% CL = 1.11-5.00). In lamotrigine subjects, 1 ABCB1 missense polymorphism (rs2032582/S893A; p = 0.015, OR = 2.22, 95% CL = 1.16-4.17) was more common in not-seizure-free participants, and 2 CACNA1H polymorphisms (rs2753326, rs2753325) were more common in seizure-free participants (p = 0.038, OR = 0.52, 95% CL = 0.28-0.96). In valproate subjects, no common polymorphisms were associated with seizure status. In vitro electrophysiological studies showed no effect of the P640L polymorphism on channel physiology in the absence of ethosuximide. Ethosuximide's effect on rate of decay of CaV 3.2 was significantly less for P640L channel compared to wild-type channel. INTERPRETATION: Four T-type calcium channel variants and 1 ABCB1 transporter variant were associated with differential drug response in CAE. The in vivo P640L variant's ethosuximide effect was confirmed by in vitro electrophysiological studies. This suggests that genetic variation plays a role in differential CAE drug response. Ann Neurol 2017;81:444-453.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Glauser TA, Holland K, O'Brien VP, et al. Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy. Ann Neurol. 2017. PMID: 28165634. doi:10.1002/ana.24886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。